-
2
-
-
79958043675
-
-
(eds)., National Cancer Institute., Bethesda, MD, based on November 2015 SEER data submission, posted to the SEER web site, April 2016. Last accessed 1 December 2016
-
Howlader N, Noone AM, Krapcho M, et al. (eds). SEER cancer statistics review, 1975-2013, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016. Last accessed 1 December 2016
-
SEER cancer statistics review, 1975-2013
-
-
Howlader, N.1
Noone, A.M.2
Krapcho, M.3
-
3
-
-
79952078495
-
Biology, risk stratification, and therapy of pediatric acute leukemias: an update
-
Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011;29:551–565.
-
(2011)
J Clin Oncol
, vol.29
, pp. 551-565
-
-
Pui, C.H.1
Carroll, W.L.2
Meshinchi, S.3
Arceci, R.J.4
-
4
-
-
0032482394
-
Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy
-
Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338:1663–1671.
-
(1998)
N Engl J Med
, vol.338
, pp. 1663-1671
-
-
Nachman, J.B.1
Sather, H.N.2
Sensel, M.G.3
-
5
-
-
84863772728
-
Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group
-
Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol. 2012;30:1663–1669.
-
(2012)
J Clin Oncol
, vol.30
, pp. 1663-1669
-
-
Hunger, S.P.1
Lu, X.2
Devidas, M.3
-
6
-
-
76749111534
-
Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001
-
Mitchell C, Richards S, Harrison CJ, Eden T. Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001. Leukemia. 2010;24:406–418.
-
(2010)
Leukemia
, vol.24
, pp. 406-418
-
-
Mitchell, C.1
Richards, S.2
Harrison, C.J.3
Eden, T.4
-
7
-
-
84865168175
-
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?
-
Pui CH, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood. 2012;120:1165–1174.
-
(2012)
Blood
, vol.120
, pp. 1165-1174
-
-
Pui, C.H.1
Mullighan, C.G.2
Evans, W.E.3
Relling, M.V.4
-
8
-
-
60949101218
-
Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study
-
Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009;27:911–918.
-
(2009)
J Clin Oncol
, vol.27
, pp. 911-918
-
-
Huguet, F.1
Leguay, T.2
Raffoux, E.3
-
9
-
-
84903557769
-
Frontline-treatment of acute lymphoblastic leukemia (ALL) in older adolescents and young adults (AYA) using a pediatric regimen is feasible: toxicity results of the prospective US Intergroup Trial C10403 (Alliance)
-
abstract
-
Advani AS, Sanford B, Luger S, et al. Frontline-treatment of acute lymphoblastic leukemia (ALL) in older adolescents and young adults (AYA) using a pediatric regimen is feasible: toxicity results of the prospective US Intergroup Trial C10403 (Alliance). Blood. 2013;122:3903; abstract.
-
(2013)
Blood
, vol.122
, pp. 3903
-
-
Advani, A.S.1
Sanford, B.2
Luger, S.3
-
10
-
-
28444490353
-
Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993
-
Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106:3760–3767.
-
(2005)
Blood
, vol.106
, pp. 3760-3767
-
-
Rowe, J.M.1
Buck, G.2
Burnett, A.K.3
-
11
-
-
33846869976
-
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study
-
Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109:944–950.
-
(2007)
Blood
, vol.109
, pp. 944-950
-
-
Fielding, A.K.1
Richards, S.M.2
Chopra, R.3
-
12
-
-
34548136113
-
Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial
-
Tavernier E, Boiron JM, Huguet F, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia. 2007;21:1907–1914.
-
(2007)
Leukemia
, vol.21
, pp. 1907-1914
-
-
Tavernier, E.1
Boiron, J.M.2
Huguet, F.3
-
13
-
-
84866094086
-
Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation
-
Gokbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120:2032–2041.
-
(2012)
Blood
, vol.120
, pp. 2032-2041
-
-
Gokbuget, N.1
Stanze, D.2
Beck, J.3
-
15
-
-
79551641737
-
Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia
-
Piccaluga PP, Arpinati M, Candoni A, et al. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia. Leuk Lymphoma. 2011;52:325–327.
-
(2011)
Leuk Lymphoma
, vol.52
, pp. 325-327
-
-
Piccaluga, P.P.1
Arpinati, M.2
Candoni, A.3
-
16
-
-
0029025026
-
Constitutive endocytosis and degradation of CD22 by human B cells
-
Shan D, Press OW. Constitutive endocytosis and degradation of CD22 by human B cells. J Immunol. 1995;154:4466–4475.
-
(1995)
J Immunol
, vol.154
, pp. 4466-4475
-
-
Shan, D.1
Press, O.W.2
-
17
-
-
33748778482
-
Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab
-
Carnahan J, Stein R, Qu Z, et al. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol. 2007;44:1331–1341.
-
(2007)
Mol Immunol
, vol.44
, pp. 1331-1341
-
-
Carnahan, J.1
Stein, R.2
Qu, Z.3
-
19
-
-
0030993376
-
CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling
-
Tedder TF, Tuscano J, Sato S, Kehrl JH. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol. 1997;15:481–504.
-
(1997)
Annu Rev Immunol
, vol.15
, pp. 481-504
-
-
Tedder, T.F.1
Tuscano, J.2
Sato, S.3
Kehrl, J.H.4
-
20
-
-
0033673757
-
Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research
-
Thorson JS, Sievers EL, Ahlert J, et al. Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research. Curr Pharm Des. 2000;6:1841–1879.
-
(2000)
Curr Pharm Des
, vol.6
, pp. 1841-1879
-
-
Thorson, J.S.1
Sievers, E.L.2
Ahlert, J.3
-
21
-
-
0023820894
-
Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically
-
Zein N, Sinha AM, McGahren WJ, Ellestad GA. Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science. 1988;240:1198–1201.
-
(1988)
Science
, vol.240
, pp. 1198-1201
-
-
Zein, N.1
Sinha, A.M.2
McGahren, W.J.3
Ellestad, G.A.4
-
22
-
-
0042303836
-
Antibody-targeted chemotherapy with immunoconjugates of calicheamicin
-
Damle NK, Frost P. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. Curr Opin Pharmacol. 2003;3:386–390.
-
(2003)
Curr Opin Pharmacol
, vol.3
, pp. 386-390
-
-
Damle, N.K.1
Frost, P.2
-
23
-
-
0036007596
-
Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia
-
Hamann PR, Hinman LM, Hollander I, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem. 2002;13:47–58.
-
(2002)
Bioconjug Chem
, vol.13
, pp. 47-58
-
-
Hamann, P.R.1
Hinman, L.M.2
Hollander, I.3
-
24
-
-
84856710962
-
The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells
-
de Vries JF, Zwaan CM, De Bie M, et al. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia. 2012;26:255–264.
-
(2012)
Leukemia
, vol.26
, pp. 255-264
-
-
de Vries, J.F.1
Zwaan, C.M.2
De Bie, M.3
-
25
-
-
84880574025
-
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia
-
Kantarjian H, Thomas D, Jorgensen J, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013;119:2728–2736.
-
(2013)
Cancer
, vol.119
, pp. 2728-2736
-
-
Kantarjian, H.1
Thomas, D.2
Jorgensen, J.3
-
26
-
-
84860243682
-
Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma
-
Ogura M, Hatake K, Ando K, et al. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. Cancer Sci. 2012;103:933–938.
-
(2012)
Cancer Sci
, vol.103
, pp. 933-938
-
-
Ogura, M.1
Hatake, K.2
Ando, K.3
-
27
-
-
84969791849
-
Preclinical to clinical translation of antibody-drug conjugates using PK/PD modeling: a retrospective analysis of inotuzumab ozogamicin
-
Betts AM, Haddish-Berhane N, Tolsma J, et al. Preclinical to clinical translation of antibody-drug conjugates using PK/PD modeling: a retrospective analysis of inotuzumab ozogamicin. AAPS J. 2016;18:1101–1116.
-
(2016)
AAPS J.
, vol.18
, pp. 1101-1116
-
-
Betts, A.M.1
Haddish-Berhane, N.2
Tolsma, J.3
-
28
-
-
10744229449
-
Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies
-
DiJoseph JF, Armellino DC, Boghaert ER, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood. 2004;103:1807–1814.
-
(2004)
Blood
, vol.103
, pp. 1807-1814
-
-
DiJoseph, J.F.1
Armellino, D.C.2
Boghaert, E.R.3
-
29
-
-
4544320025
-
Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma
-
DiJoseph JF, Goad ME, Dougher MM, et al. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin Cancer Res. 2004;10:8620–8629.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 8620-8629
-
-
DiJoseph, J.F.1
Goad, M.E.2
Dougher, M.M.3
-
30
-
-
77951648118
-
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study
-
Advani A, Coiffier B, Czuczman MS, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol. 2010;28:2085–2093.
-
(2010)
J Clin Oncol
, vol.28
, pp. 2085-2093
-
-
Advani, A.1
Coiffier, B.2
Czuczman, M.S.3
-
31
-
-
84875434050
-
Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab
-
Fayad L, Offner F, Smith MR, et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol. 2013;31:573–583.
-
(2013)
J Clin Oncol
, vol.31
, pp. 573-583
-
-
Fayad, L.1
Offner, F.2
Smith, M.R.3
-
32
-
-
84938897233
-
A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma
-
Wagner-Johnston ND, Goy A, Rodriguez MA, et al. A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2015;56:2863–2869.
-
(2015)
Leuk Lymphoma
, vol.56
, pp. 2863-2869
-
-
Wagner-Johnston, N.D.1
Goy, A.2
Rodriguez, M.A.3
-
33
-
-
35548931579
-
Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia
-
Dijoseph JF, Dougher MM, Armellino DC, Evans DY, Damle NK. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia. 2007;21:2240–2245.
-
(2007)
Leukemia
, vol.21
, pp. 2240-2245
-
-
Dijoseph, J.F.1
Dougher, M.M.2
Armellino, D.C.3
Evans, D.Y.4
Damle, N.K.5
-
34
-
-
84862786326
-
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
-
Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13:403–411.
-
(2012)
Lancet Oncol
, vol.13
, pp. 403-411
-
-
Kantarjian, H.1
Thomas, D.2
Jorgensen, J.3
-
35
-
-
84890875516
-
Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia
-
Rytting M, Triche L, Thomas D, O'Brien S, Kantarjian H. Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia. Pediatr Blood Cancer. 2014;61:369–372.
-
(2014)
Pediatr Blood Cancer
, vol.61
, pp. 369-372
-
-
Rytting, M.1
Triche, L.2
Thomas, D.3
O'Brien, S.4
Kantarjian, H.5
-
36
-
-
84982898563
-
A phase II Study of Weekly Inotuzumab Ozogamicin (InO) in adult patients with CD22-positive acute lymphoblastic leukemia (ALL) in second or later salvage
-
abstract
-
Advani AS, Stein AS, Kantarjian HM, et al. A phase II Study of Weekly Inotuzumab Ozogamicin (InO) in adult patients with CD22-positive acute lymphoblastic leukemia (ALL) in second or later salvage. Blood. 2014;124:2255; abstract.
-
(2014)
Blood
, vol.124
, pp. 2255
-
-
Advani, A.S.1
Stein, A.S.2
Kantarjian, H.M.3
-
37
-
-
79955047304
-
Treating the “older” adult with acute lymphoblastic leukemia
-
Marks DI. Treating the “older” adult with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2010;2010:13–20.
-
(2010)
Hematology Am Soc Hematol Educ Program
, vol.2010
, pp. 13-20
-
-
Marks, D.I.1
-
38
-
-
84988217496
-
Inotuzumab ozogamicin (IO) in combination with low-intensity chemotherapy as front-line therapy for older patients (pts) and as salvage therapy for adult with R/R acute lymphoblastic leukemia (ALL)
-
Jabbour E, O'Brien SM, Jain N, et al. Inotuzumab ozogamicin (IO) in combination with low-intensity chemotherapy as front-line therapy for older patients (pts) and as salvage therapy for adult with R/R acute lymphoblastic leukemia (ALL). J Clin Oncol. 2014;32(5 Suppl):abstr 7019.
-
(2014)
J Clin Oncol
, vol.32
, Issue.5
, pp. abstr 7019
-
-
Jabbour, E.1
O'Brien, S.M.2
Jain, N.3
-
39
-
-
84984677465
-
Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia
-
Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375:740–753.
-
(2016)
N Engl J Med
, vol.375
, pp. 740-753
-
-
Kantarjian, H.M.1
DeAngelo, D.J.2
Stelljes, M.3
-
40
-
-
84923071079
-
Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody
-
Jabbour E, O'Brien S, Huang X, et al. Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. Am J Hematol. 2015;90:193–196.
-
(2015)
Am J Hematol
, vol.90
, pp. 193-196
-
-
Jabbour, E.1
O'Brien, S.2
Huang, X.3
-
41
-
-
84877733104
-
Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin
-
Kebriaei P, Wilhelm K, Ravandi F, et al. Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin. Clin Lymphoma Myeloma Leuk. 2013;13:296–301.
-
(2013)
Clin Lymphoma Myeloma Leuk
, vol.13
, pp. 296-301
-
-
Kebriaei, P.1
Wilhelm, K.2
Ravandi, F.3
|